Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell
- Castle Creek will advance multiple late-stage clinical development programs targeting epidermolysis bullosa - PARSIPPANY, N.J., September 12, 2019 -- Castle Creek Pharmaceutical Holdings, Inc. (“CCP Holdings”) today announced it has reached an agreement to acquire Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin